We have developed a lidocaine nanocomposite patch using our innovative nanocomposite patch technology which offers a tangible and better alternative to currently available options.

WHY A LIDOCAINE PATCH?

• A quick route to the market: Lidocaine has proven safety profile for the treatment of post-herpetic neuralgia (PHN) (Lidoderm®, Versatis®). All components of our patch are FDA approved for topical/transdermal applications would further expedite regulatory processes.
• To prove the safety of our nanocomposite patch system: In addition to expediting our patch development through early clinical stages, this will also provide a clean baseline to showcase the potential of this novel delivery system.
• Growing market: Representing roughly a market of 1 billion USD (IMS health 2015), the lidocaine market continues to grow, driven by an ageing population. There is growing evidence that lidocaine based pain relief can be used for other neuropathies e.g. diabetic foot.
• Need for a differentiator technology: With the European patent (for Versatis®) expiry in 2017, companies are actively looking for a technology that could give them an edge over the generics.

OUR SOLUTION

• The current lidocaine patch uses a high dose of drug with ~97% remaining in the used patch when discarded. It can only be applied for 12 H with a 12H break due to adverse skin reaction to high levels of lidocaine in the patch.
• We have produced a highly efficient and biocompatible nanocomposite lidocaine patch: It has the potential for >24H application with the similar release rates as obtained with the current commercial patches. This is achieved using 30x lower dose with less than 5% leftover after use.